Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biomet Spinal Business Expansion Backs 15% Stock Gain In February

This article was originally published in The Gray Sheet

Executive Summary

Biomet's rapidly expanding spinal business and accelerating reconstructive device revenues, coupled with a history of predictable earnings growth, helped the firm's stock advance 15.2% during a generally chilly February for device issues. The stock closed the month at $38.81, a gain of $5.12.

You may also be interested in...

Biomet's $90 Mil. Cash Biolectron Buy Adds SpinalPak Spinal Stimulator

Biomet's $90 mil. cash acquisition of privately-held Biolectron will add the SpinalPak non-invasive spinal stimulator to Biomet's existing orthopedic offerings and complement the firm's SpF implantable spinal fusion stimulation product, Biomet says.

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts